

Board of Governors of the Federal Reserve System, August 5, 2002.

**Robert deV. Frierson,**

*Deputy Secretary of the Board.*

[FR Doc. 02-20088 Filed 8-7-02; 8:45 am]

**BILLING CODE 6210-01-S**

## FEDERAL RETIREMENT THRIFT INVESTMENT BOARD

### Sunshine Act Notice

**TIME AND DATE:** 10 a.m. (EDT) August 19, 2002.

**PLACE:** 4th Floor, Conference Room, 1250 H Street, NW., Washington, DC.

**STATUS:** Parts will be open to the public and part closed to the public.

### Matters To Be Considered

Parts Open to the Public

1. Approval of the minutes of the July 15, 2002, Board member meeting.
2. Thrift Savings Plan activity report by the Executive Director (with discussion of litigation to be closed to the public).
3. Review of investment policy.
4. Review of Ernst & Young semiannual financial review.

### Part Closed to the Public

Discussion of litigation.

**CONTACT PERSON FOR MORE INFORMATION:** Thomas J. Trabucco, Director, Office of External Affairs, (202) 942-1640.

Dated: August 6, 2002.

**Elizabeth S. Woodruff,**

*Secretary to the Board, Federal Retirement Thrift Investment Board.*

[FR Doc. 02-20263 Filed 8-6-02; 3:33 pm]

**BILLING CODE 6760-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Notice of Interest Rate on Overdue Debts

Section 30.13 of the Department of Health and Human Services' claims collection regulations (45 CFR part 30) provides that the Secretary shall charge an annual rate of interest as fixed by the Secretary of the Treasury after taking into consideration private consumer rates of interest prevailing on the date that HHS become entitled to recovery. The rate generally cannot be lower than the Department of Treasury's current value of funds rate or the applicable rates determined from the "Schedule of Certified Interest Rates with Range of Maturities." This rate may be revised quarterly by the Secretary of the Treasury and shall be published

quarterly by the Department of Health and Human Services in the **Federal Register**.

The Secretary of the Treasury has certified a rate of 12<sup>5</sup>/<sub>8</sub>% for the quarter ended June 30, 2002. This interest rate will remain in effect until such time as the Secretary of the Treasury notifies HHS of any change.

Dated: July 31, 2002.

**George Strader,**

*Deputy Assistant Secretary, Finance*

[FR Doc. 02-20020 Filed 8-7-02; 8:45 am]

**BILLING CODE 4150-04-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following Federal advisory committee meeting.

*Name:* National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect (NTFFASFAE).

*Times and Dates:*

8:30 a.m.-4:30 p.m., September 20, 2002.

8:30 a.m.-12 noon, September 21, 2002.

*Place:* Hyatt Regency, 265 Peachtree Street, N.E., Atlanta, Georgia 30303, telephone 404/577-1234, fax 404/588-3752.

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 65 people.

*Purpose:* The Secretary is authorized by the Public Health Service Act, section 399H, (42 U.S.C. 280f, as added by Public Law 105-392) to establish a National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect to: (1) Foster coordination among all governmental agencies, academic bodies and community groups that conduct or support Fetal Alcohol Syndrome (FAS) and Fetal Alcohol Effect (FAE) research, programs and surveillance; and (2) to otherwise meet the general needs of populations actually or potentially impacted by FAS and FAE.

*Matters To Be Discussed:* Discussions will focus on ways the Task Force can collaborate with CDC and other Federal agencies on issues of diagnostic criteria for FAS/Alcohol Related Neurodevelopmental Disorder (ARND) in order to enhance health care providers' recognition of these disorders, and to ensure that those affected and their families receive needed services; the special needs of birth mothers of children with FAS/ARND; a report of the Substance Abuse and Mental Health Services Administration FAS/FAE Center for Excellence on their initial "stakeholders" meetings and future plans; an update on activities from the Interagency Coordinating Committee on Fetal Alcohol Syndrome; new research and program

updates from the CDC; and a discussion of the implementation of the Task Force recommendations by various governmental agencies. Additional agenda items include: Working group updates; discussion of future topics, and scheduling the next meeting.

Agenda items are subject to change as priorities dictate.

*Contact Person for More Information:* R. Louise Floyd, DSN, RN, Designated Federal Official, National Center on Birth Defects and Developmental Disabilities, CDC, 4700 Buford Highway, NE, (F-49), Atlanta, Georgia 30333, telephone 770/488-7372, fax 770/488-7361.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the CDC and ATSDR.

Dated: August 2, 2002.

**John Burckhardt,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 02-20037 Filed 8-7-02; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Prospective Grant of Exclusive License: Various Retrovirus Isolated From Humans

**AGENCY:** Technology Transfer Office, Centers for Disease Control and Prevention (CDC), Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** This is a notice in accordance with 35 U.S.C. 209 (e) and 37 CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention (CDC), Technology Transfer Office, Department of Health and Human Services (DHHS), is contemplating the grant of a worldwide exclusive license to practice the inventions embodied in the patents and patent applications referred to below to Antibody Systems, Inc., located in Hurst, Texas. The patent rights in these inventions have been assigned to the government of the United States of America. The patents and patent applications to be licensed are:

*Title:* Retrovirus Isolated from Humans, U.S. Patent No. 5,882,912. Issue Date: 03/16/99. CDC Reference No. I-012-97/0; New Spumavirus Isolated from Humans, U.S. Patent Application PCT/US98/02598 dated 2/12/98. CDC Reference No. I-012-97/1; Spumavirus

Isolated from Humans, U.S. Patent Application 09/367,213 dated 12/08/1999. CDC Reference No. I-012-97/2; New Retrovirus Isolated from Humans, U.S. Patent Application PCT/US01/51411 dated 10.19.2001. CDC Reference No. I-023-00/0 Spumavirus Isolated from Humans, U.S. Patent Application PCT/US99/25171 dated 10/27/99. CDC Reference No. I-034-97/0; Spumavirus Isolated from Humans, U.S. Patent Application Serial No. 09/830,616 filed 9/05/01. CDC Reference No. I-034-97/1;

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

These inventions cover unique spumavirus isolates and clones from infected humans, and an infectious spumavirus vector. Licensee will further development this technology to assess this vector's suitability for gene therapy applications, attenuated vaccines, and use as a stable replicating viral vector.

**ADDRESSES:** Requests for a copy of the patent applications, inquiries, comments, and other materials relating to the contemplated license should be directed to Andrew Watkins, Director, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, Mailstop K-79, Atlanta, GA 30341, telephone: (770) 488-8600; facsimile: (770) 488-8615. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by CDC within sixty days of this notice will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. A signed Confidential Disclosure Agreement will be required to receive a copy of any pending patent application.

Dated: August 2, 2002.

**Joseph R. Carter,**

*Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 02-20039 Filed 8-7-02; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### National Health and Nutrition Examination Survey III (NHANES) DNA Specimens: Guidelines for Proposals to Use Samples and Proposed Cost Schedule

**ACTION:** Notice.

**SUMMARY:** The National Health and Nutrition Examination Survey (NHANES) is a program of periodic surveys conducted by the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC). Examination surveys conducted since 1960 by NCHS have provided national estimates of the health and nutritional status of the U.S. civilian non-institutionalized population. To add to the large amount of information collected for the purpose of describing the health of the population, blood lymphocytes were collected in NHANES III in anticipation of advances in genetic research.

The lymphocytes have been stored and maintained at the Division of Laboratory Sciences (DLS) at the National Center for Environmental Health (NCEH), CDC. The collection of lymphocytes was begun in the second phase of the survey (1991-1994) because of the significant advances in the rapidly evolving field of molecular biology that were occurring during the planning phase of this survey. CDC is making DNA samples from these specimens available to the research community for such analyses. Specimens are available from approximately 7,300 participants in the second phase of NHANES III. No cell lines will be made available.

This program has been previously announced (Tuesday, June 1, 1999 (64 FR 29321)). The purpose of this notice is to announce a third category for proposals for use of these specimens and a new cost schedule. For final proposal guidelines and request for letters of intent, please contact Ms. Oraegbu or go to <http://www.cdc.gov/nchs/about/major/nhanes/dnafnlgm2.htm>.

All interested researchers are encouraged to submit letters of intent. Approximately twenty proposals for a full set of specimens (~7,300 samples) and a limited number of proposals (less than five, depending on the number of specimens requested) for smaller sets of samples can be awarded in this solicitation. No funding is provided as

part of this solicitation. Proposals will be reviewed by a technical panel. Approved projects that do not obtain funding on their own will be canceled. A more complete description of this program follows.

#### Dates

- Letter of Intent Receipt: September 9, 2002
- Submission of Proposals: October 7, 2002
- Application Receipt: November 18, 2002
- Scientific Review: January, 2003
- Institutional Review: February, 2003
- Notification of approval: March 2003
- Anticipated distribution of samples: July-August 2003

**ADDRESSES:** To send comments and for information, contact:

Ms. Kika Oraegbu, Division of Health Examination Statistics, National Center for Health Statistics, Centers for Disease Control and Prevention, 6525 Belcrest Road, Room 1000, Hyattsville, MD 20782, Phone: 301-458-4367, FAX: 301-458-4028, E-Mail: [KDO1@cdc.gov](mailto:KDO1@cdc.gov), Internet: <http://www.cdc.gov/nchs/about/major/nhanes/dnafnlgm2.htm>.

#### SUPPLEMENTARY INFORMATION:

The goals of NHANES are (1) to estimate the number and percentage of people in the U.S. population and designated subgroups with selected diseases and risk factors for those diseases; (2) to monitor trends in the prevalence, awareness, treatment and control of selected diseases; (3) to monitor trends in risk behaviors and environmental exposures; (4) to analyze risk factors for selected diseases; (5) to study the relation among diet, nutrition and health; (6) to explore emerging public health issues and new technologies; (7) to establish and maintain a national probability sample of baseline information on health and nutrition status.

The Third National Health and Nutrition Examination Survey (NHANES III) began in the Fall of 1988 and ended in the Fall of 1994. Survey data were collected and can be analyzed from two phases: Phase I was conducted from October 1988 to October 1991, and Phase II was conducted from October 1991 to October 1994. Both phases are nationally representative samples. For details of the sampling design see the Plan and Operation of NHANES III (1). This information can be obtained by contacting the Data Dissemination Branch, NCHS, at 301-458-4636 or from the Internet at <http://www.cdc.gov/nchs/about/major/nhanes/nh3data.htm>.